Remicade

Celltrion eyes biosim Remicade launch in the U.S. this year
Celltrion eyes biosim Remicade launch in the U.S. this year
Fierce Pharma Marketing
Celltrion
biosimilars
Remicade
Flag link:
Merck touts a bright future in biosimilars with a stable of would-be blockbusters
Merck touts a bright future in biosimilars with a stable of would-be blockbusters
Fierce Biotech
Merck
biosimilars
AbbVie
Humira
JNJ
Remicade
Amgen
Enbrel
Samsung Bioepis
Biogen Idec
Flag link:
FDA postpones key hearing on biosimilar copy of blockbuster drug
FDA postpones key hearing on biosimilar copy of blockbuster drug
Yahoo/Reuters
FDA
biosimilars
Rensima
Remicade
JNJ
rheumatoid arthritis
Crohn's Disease
Hospira
Celltrion
Flag link:
Celltrion, Hospira avoid biosimilar traffic jam in U.S.
Celltrion, Hospira avoid biosimilar traffic jam in U.S.
BioCentury
Celltrion
Hospira
biosimilars
Remicade
Flag link:
FirstWord Lists – The best selling drugs in 2014
FirstWord Lists – The best selling drugs in 2014
First Word Pharma
Humira
Sovaldi
Remicade
Enbrel
Lantus
Rituxan
Advair
Avastin
Herceptin
Januvia
Merck
AbbVie
Gilead Sciences
JNJ
Amgen
Pfizer
Sanofi
Roche
GSK
Flag link:
Johnson & Johnson Faces Pressure From U.S. Patent Office
Johnson & Johnson Faces Pressure From U.S. Patent Office
Yahoo/Benzinga
JNJ
patents
Remicade
Flag link:
Competition to J&J's Remicade looms in U.S. as biosimilar conquers new markets
Competition to J&J's Remicade looms in U.S. as biosimilar conquers new markets
Fierce Biotech
JNJ
Remicade
biosimilars
FDA
Celltrion
Remsima
Flag link:
Abandonment rates indicate room in the anti-TNF market
Abandonment rates indicate room in the anti-TNF market
Medical Marketing and Media
anti-TNF
JNJ
Remicade
Humira
AbbVie
Biogen Idec
Flag link:
Most Popular News Headlines For Monday, August 11 2014
Most Popular News Headlines For Monday, August 11 2014
CP Wire
Celltrion
Remsima
Jannsen
Remicade
Invokamet
JNJ
Sanofi
Cologuard
MannKind
Afrezza
EXACT Sciences
Flag link:
Most popular news headlines for Monday, August 11 2014
Celltrion
Remsima
Jannsen
Remicade
Invokamet
JNJ
Sanofi
Cologuard
MannKind
Afrezza
EXACT Sciences
Flag link:
FDA Accepts First-Ever Biosimilar Application for Monoclonal Antibody
FDA Accepts First-Ever Biosimilar Application for Monoclonal Antibody
RAPS.org
Remsima
Remicade
monoclonal antibodies
FDA
Celltrion
biosimilars
Flag link:
Drugs That Will Help Johnson & Johnson Grow By 5% In 2014
Drugs That Will Help Johnson & Johnson Grow By 5% In 2014
Forbes
JNJ
Remicade
Olysio
Velcade
Zytiga
Flag link:
A Second Lawsuit Tests the BPCIA Biosimilars “Patent Dance” Waters
A Second Lawsuit Tests the BPCIA Biosimilars “Patent Dance” Waters
FDA Law Blog
patents
biosimilars
Celltrion
Janssen Biotech
Remicade
Flag link:
The 10 best-selling drugs of 2013
The 10 best-selling drugs of 2013
Fierce Pharma
Seretide
Rituxan
Remicade
MabThera
Lantus
Humira
Herceptin
Enbrel
Crestor
Avastin
Advair
Abilify
Flag link:
Johnson & Johnson's Real Answer To Imminent Decline In Sales Of Top-Selling Drug
Johnson & Johnson's Real Answer To Imminent Decline In Sales Of Top-Selling Drug
Seeking Alpha
JNJ
Remicade
Olysio
hepatitis C
Flag link:
Celgene Vs. Rivals In Psoriatic Arthritis Drug Race
Celgene Vs. Rivals In Psoriatic Arthritis Drug Race
Seeking Alpha
psoriatic arthritis
Celgene
AbbVie
Amgen
JNJ
Merck
Humira
apremilast
Enbrel
Stelara
Simponi
Remicade
Flag link:
The 3 Best-Selling Drugs in the World
The 3 Best-Selling Drugs in the World
Motley Fool
AbbVie
Humira
Remicade
JNJ
GSK
Advair
Flag link:
Johnson & Johnson Continues To Ride The Success Of Its Immunology And Oncology Drugs
Johnson & Johnson Continues To Ride The Success Of Its Immunology And Oncology Drugs
Seeking Alpha
JNJ
Remicade
Simponi
Stelara
Invokana
Flag link:
Top 10 rheumatoid arthritis drugs 2013
Top 10 rheumatoid arthritis drugs 2013
Fierce Pharma
rheumatoid arthritis
Humira
AbbVie
Enbrel
Amgen
Remicade
Janssen
Celebrex
Pfizer
Bristol-Myers Squibb
Orencia
Cimza
UCB
Simponi
JNJ
Arthrotec
Vimovo
AstraZeneca
Kineret
Flag link:
Will This Biotech Approval Start a $100 Billion Trend?
Will This Biotech Approval Start a $100 Billion Trend?
Motley Fool
drug approvals
Hospira
Remicade
biosimilars
Flag link:

Pages